Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangxi Institute of Biological Products Current Ratio?
Jiangxi Institute of Biological ProductsHKSE:06915 +1.33%23 Current Ratio is 4.20 as of Dec. 2025, which is 83% above its 10-year median of 2.30. GuruFocus rates HKSE:06915 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 998 Drug Manufacturers companies, Jiangxi Institute of Biological Products ranks better than 80.36% on this metric.
Jiangxi Institute of Biological Products has a current ratio of 4.20. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
Jiangxi Institute of Biological Products (HKSE:06915) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Jiangxi Institute of Biological Products Current Ratio Related Terms
Jiangxi Institute of Biological Products Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products Current Ratio Chart
Jiangxi Institute of Biological Products Annual Data
Trend
Dec23
Dec24
Dec25
Current Ratio
1.39
2.30
4.20
Jiangxi Institute of Biological Products Semi-Annual Data
Dec23
Dec24
Dec25
Current Ratio
1.39
2.30
4.20
HKSE:06915 vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Jiangxi Institute of Biological Products's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Institute of Biological Products Current Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products (HKSE:06915) has a Current Ratio of 4.20 as of Dec. 2025. This is 83% above median its historical median of 2.30. Over the past decade, Jiangxi Institute of Biological Products' Current Ratio has ranged from 1.39 to 4.20. According to the industry distribution chart, Jiangxi Institute of Biological Products ranks #196 out of 998 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Jiangxi Institute of Biological Products' Current Ratio too high?
Jiangxi Institute of Biological Products' current Current Ratio of 4.20 is 83% above median its 10-year median of 2.30. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 4.20. The Drug Manufacturers industry median Current Ratio is 1.92. Jiangxi Institute of Biological Products' value of 4.20 is 118.8% above this industry median. Based on the distribution chart, Jiangxi Institute of Biological Products ranks #196 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Jiangxi Institute of Biological Products ranks #196 out of 998 companies for Current Ratio. This places Jiangxi Institute of Biological Products in the top 20% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.92. Jiangxi Institute of Biological Products' value of 4.20 is 118.8% above this benchmark. Historically, Jiangxi Institute of Biological Products' own Current Ratio has ranged from 1.39 to 4.20 over the past decade. While the company's 10-year median is 2.30 vs. the industry median of 1.92, Jiangxi Institute of Biological Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.92, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangxi Institute of Biological Products's current Current Ratio of 4.20 is 118.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Institute of Biological Products's current Current Ratio is 4.20, which is 83% above median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current Current Ratio of 4.20. The current Current Ratio is 4.20, which is 83% above median its 10-year median of 2.30 and 118.8% above the Drug Manufacturers industry median of 1.92. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current Current Ratio is 4.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score
Get the complete analysis for HKSE:06915
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06915 has been successfully added to your 
